KDM5B and prostate carcinoma: The combined inhibition of KDM5B and LSD1 with the use of CPI-455 and namoline, respectively, led to reduced expression of AR-responsive genes and reduced cell proliferation and invasion in both castration-sensitive and castration-resistant prostate cancer cells [102].